Helixmith Obtains Patent for 'Anti-Sialyl Tn Chimeric Antigen Receptor'
[Asia Economy Reporter Minwoo Lee] Helixmith announced on the 17th that it has obtained a Japanese patent for 'Anti-Sialyl Tn Chimeric Antigen Receptors (ANTI-SIALYL TN CHIMERIC ANTIGEN RECEPTORS)'.
Hot Picks Today
"Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- "Striking Will Lead to Regret": Hyundai-Kia Employees Speak Out... Uneasy Stares Toward Samsung Union
- Man in His 40s Who Kept Girlfriend's Body for a Year After Murder Sentenced to 30 Years in Prison Again on Appeal
- Despite Captivating the Nation for Over a Month... "Timmy" the Whale Ultimately Found Dead
- "If You Booked This Month, You Almost Lost Out... Why You Should Wait Until 'This Day' Before Paying for Flight Tickets"
The company stated, "This pertains to anti-sialyl Tn chimeric antigen receptors for adoptive cell therapy targeting cancers expressing the sialyl Tn antigen (STn) on the TAG-72 (tumor associated glycoprotein 72) glycoprotein, the cells expressing these receptors, and compositions thereof," adding, "It can be utilized in the development of anticancer gene cell therapies for solid tumors such as colorectal cancer, ovarian cancer, gastric cancer, breast cancer, esophageal cancer, bladder cancer, lung cancer, and pancreatic cancer where TAG-72 is expressed."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
